FDA Clearance Tracker · P160025-S005
Astron Pulsar and Pulsar-18 Stent Systems
Last checked: Nov 20, 2026Latest source record: Aug 22, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Aug 22, 2018
Approved
Time to decision
62 days
Received Jun 21, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P160025-S005
- Device name
- Astron Pulsar and Pulsar-18 Stent Systems
- Applicant
- Biotronik AG
- Applicant location
- BüLach
- Received
- Jun 21, 2018
- Decided
- Aug 22, 2018
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P160025
Device type
- Device type
- STENT, SUPERFICIAL FEMORAL ARTERY (NIP)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for updated labeling to include clinical data from the BIOFLEX-I Study.
Source documents
Other decisions for Biotronik AG
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P170030 · Decided Feb 22, 2019 · 513 days after receipt
Device type: Coronary drug-eluting stent (NIQ) · Cardiology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.